Neumora Therapeutics IncNASDAQ:NMRA
- LAST PRICE9.8300
- TODAY'S CHANGE (%)0.1600 (1.6546%)
- Bid / Lots9.8200/ 6
- Ask / Lots9.8400/ 2
- Open / Previous Close9.6500 / 9.6700
- Day Range
- 52 Week Range
- Volume275,459
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | NMRA |
|---|---|---|
| 09:32 ET | 10573 | 9.65 |
| 09:33 ET | 1222 | 9.79 |
| 09:35 ET | 334 | 9.7496 |
| 09:37 ET | 400 | 9.785 |
| 09:39 ET | 589 | 9.7765 |
| 09:42 ET | 802 | 9.76 |
| 09:44 ET | 1317 | 9.7 |
| 09:46 ET | 2943 | 9.675 |
| 09:48 ET | 900 | 9.68 |
| 09:50 ET | 7249 | 9.72 |
| 09:51 ET | 5218 | 9.68 |
| 09:53 ET | 488 | 9.665 |
| 09:55 ET | 1624 | 9.71 |
| 09:57 ET | 2979 | 9.635 |
| 10:00 ET | 3224 | 9.595 |
| 10:02 ET | 3159 | 9.61 |
| 10:04 ET | 1939 | 9.61 |
| 10:06 ET | 439 | 9.61 |
| 10:08 ET | 950 | 9.61 |
| 10:09 ET | 2315 | 9.655 |
| 10:11 ET | 400 | 9.63 |
| 10:13 ET | 692 | 9.655 |
| 10:15 ET | 1000 | 9.655 |
| 10:18 ET | 714 | 9.69 |
| 10:20 ET | 300 | 9.75 |
| 10:22 ET | 2300 | 9.695 |
| 10:24 ET | 1261 | 9.7 |
| 10:26 ET | 700 | 9.7 |
| 10:27 ET | 606 | 9.67 |
| 10:29 ET | 1650 | 9.72 |
| 10:31 ET | 3406 | 9.68 |
| 10:33 ET | 24717 | 9.68 |
| 10:36 ET | 10695 | 9.68 |
| 10:38 ET | 1865 | 9.69 |
| 10:40 ET | 1630 | 9.72 |
| 10:42 ET | 1049 | 9.69 |
| 10:44 ET | 780 | 9.72 |
| 10:45 ET | 600 | 9.76 |
| 10:47 ET | 685 | 9.79 |
| 10:51 ET | 1505 | 9.88 |
| 10:54 ET | 200 | 9.84 |
| 10:56 ET | 905 | 9.88 |
| 10:58 ET | 500 | 9.88 |
| 11:00 ET | 300 | 9.91 |
| 11:02 ET | 400 | 9.89 |
| 11:03 ET | 700 | 9.89 |
| 11:05 ET | 400 | 9.86 |
| 11:12 ET | 400 | 9.835 |
| 11:14 ET | 1300 | 9.725 |
| 11:16 ET | 300 | 9.725 |
| 11:18 ET | 1024 | 9.785 |
| 11:20 ET | 300 | 9.76 |
| 11:21 ET | 350 | 9.76 |
| 11:23 ET | 350 | 9.76 |
| 11:25 ET | 100 | 9.78 |
| 11:27 ET | 808 | 9.82 |
| 11:32 ET | 100 | 9.86 |
| 11:34 ET | 100 | 9.85 |
| 11:36 ET | 1200 | 9.815 |
| 11:38 ET | 1032 | 9.85 |
| 11:39 ET | 25815 | 9.81 |
| 11:41 ET | 1218 | 9.795 |
| 11:43 ET | 181 | 9.8 |
| 11:45 ET | 1253 | 9.7635 |
| 11:48 ET | 1122 | 9.765 |
| 11:50 ET | 100 | 9.765 |
| 11:52 ET | 359 | 9.765 |
| 11:54 ET | 300 | 9.73 |
| 11:56 ET | 1638 | 9.74 |
| 11:57 ET | 2903 | 9.73 |
| 11:59 ET | 300 | 9.735 |
| 12:01 ET | 3288 | 9.71 |
| 12:03 ET | 2855 | 9.75 |
| 12:06 ET | 100 | 9.75 |
| 12:08 ET | 936 | 9.75 |
| 12:10 ET | 600 | 9.72 |
| 12:12 ET | 100 | 9.75 |
| 12:14 ET | 4014 | 9.74 |
| 12:15 ET | 926 | 9.735 |
| 12:17 ET | 300 | 9.725 |
| 12:19 ET | 4919 | 9.72 |
| 12:24 ET | 256 | 9.7465 |
| 12:28 ET | 200 | 9.71 |
| 12:30 ET | 100 | 9.71 |
| 12:32 ET | 100 | 9.71 |
| 12:33 ET | 100 | 9.73 |
| 12:35 ET | 1969 | 9.705 |
| 12:37 ET | 100 | 9.725 |
| 12:39 ET | 1206 | 9.69 |
| 12:42 ET | 1200 | 9.7 |
| 12:44 ET | 100 | 9.7 |
| 12:48 ET | 750 | 9.7 |
| 12:50 ET | 850 | 9.7 |
| 12:51 ET | 13151 | 9.7 |
| 12:57 ET | 2100 | 9.69 |
| 01:00 ET | 446 | 9.7 |
| 01:02 ET | 470 | 9.7 |
| 01:04 ET | 1239 | 9.745 |
| 01:08 ET | 202 | 9.76 |
| 01:09 ET | 100 | 9.76 |
| 01:11 ET | 300 | 9.73 |
| 01:13 ET | 391 | 9.7476 |
| 01:15 ET | 1632 | 9.79 |
| 01:22 ET | 300 | 9.79 |
| 01:24 ET | 500 | 9.79 |
| 01:26 ET | 2261 | 9.77 |
| 01:29 ET | 2735 | 9.775 |
| 01:31 ET | 500 | 9.74 |
| 01:36 ET | 100 | 9.73 |
| 01:38 ET | 1330 | 9.73 |
| 01:40 ET | 1894 | 9.76 |
| 01:42 ET | 200 | 9.755 |
| 01:44 ET | 200 | 9.78 |
| 01:45 ET | 845 | 9.79 |
| 01:47 ET | 100 | 9.805 |
| 01:49 ET | 2019 | 9.81 |
| 01:51 ET | 2360 | 9.821 |
| 01:54 ET | 100 | 9.83 |
Nov 22, 2024
DJ Neumora Therapeutics Price Target Maintained With a $29.00/Share by RBC Capital, from 12:07PM ET on Friday Nov 22, 2024 by Dow Jones
12:07PM ET on Friday Nov 22, 2024 by Dow Jones
Nov 13, 2024
DJ Neumora Therapeutics Price Target Maintained With a $30.00/Share by HC Wainwright & Co., from 11:59AM ET on Wednesday Nov 13, 2024 by Dow Jones
11:59AM ET on Wednesday Nov 13, 2024 by Dow JonesDJ Neumora Therapeutics Price Target Maintained With a $23.00/Share by Needham, from 5:20AM ET on Wednesday Nov 13, 2024 by Dow Jones
5:20AM ET on Wednesday Nov 13, 2024 by Dow Jones
Nov 12, 2024
Press Release: Neumora Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update, from 7:00AM ET on Tuesday Nov 12, 2024 by Dow Jones
7:00AM ET on Tuesday Nov 12, 2024 by Dow JonesNeumora Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update, from 7:00AM ET on Tuesday Nov 12, 2024 by Dow Jones
7:00AM ET on Tuesday Nov 12, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Neumora Therapeutics Inc | 1.6B | -5.6x | --- |
Viridian Therapeutics Inc | 1.6B | -5.1x | --- |
Spyre Therapeutics Inc | 1.6B | -3.7x | --- |
Day One Biopharmaceuticals Inc | 1.4B | -13.2x | --- |
Praxis Precision Medicines Inc | 1.4B | -7.7x | --- |
Syndax Pharmaceuticals Inc | 1.4B | -4.5x | --- |
Company Information
Neumora Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company’s therapeutic pipeline consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its advanced product candidate, navacaprant (NMRA-140), is a novel once-daily oral kappa opioid receptor (KOR) antagonist that is being developed for the treatment of depressive disorder (MDD). Its other candidates include NMRA-266, NMRA-511, and NMRA-NMDA. NMRA-266 is a positive allosteric modulator program of the M4 muscarinic receptor (M4R) for the treatment of schizophrenia. NMRA-266 is designed to be selective for the M4 receptor subtype of the muscarinic receptor family. NMRA-511 is an investigational antagonist of the vasopressin 1a receptor (V1aR). NMRA-NMDA is an NMDA positive allosteric modulator program that the Company is developing for the treatment of schizophrenia.
Contact Information
- Headquarters
- 490 Arsenal Way, Suite 200WATERTOWN, MA, United States 02472
- Phone
- 857-760-0900
- Fax
- 302-655-5049
Executives
- Executive Chairman of the Board, Co-Founder
- Paul Berns
- President, Chief Executive Officer, Director
- Henry Gosebruch
- Co-Founder, Chief Operating Officer
- Carol Suh
- Chief Financial Officer
- Joshua Pinto
- Chief Strategy Officer
- Daljit Aurora
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.6B |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 161.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-1.77 |
Book Value | $2.95 |
P/E Ratio | -5.6x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
